This article first appeared on Forbes.com Speed to market has always been critical in the life sciences industry. Companies that bring products to market quickly and efficiently are better positioned to succeed and improve patient outcomes. Or so the industry wisdom goes. For Moderna, the covid wunderkind that captured almost $40 billion in sales over the […]
963: How a Biotech Disrupter Is De-risking R&D | Jamey Mock, CFO, Moderna
It's no secret that Moderna's R&D efforts have expanded well beyond the realm of COVID-19. CFO Jamey Mock tells us that today the company has more than 40 drugs in its pipeline, with targets such as respiratory, latent, onocology and rare diseases. As he explains, this diversity means that the biotech innovator is reliant not…
Listen to the Episode Below (0:44:10)